Clinical and Translational Science Institute

Centers

12-20-2017

MitoNEET (CISD1) Knockout Mice Show Signs of Striatal
Mitochondrial Dysfunction and a Parkinson's Disease Phenotype
Werner J. Geldenhuys
West Virginia University

Stanley A. Benkovic
West Virginia University

Li Lin
Northeast Ohio Medical University

Heather M. Yonutas
University of Kentucky

Samuel D. Crish
Northeast Ohio Medical University

See next page for additional authors
Follow this and additional works at: https://researchrepository.wvu.edu/ctsi
Part of the Medicine and Health Sciences Commons

Digital Commons Citation
Geldenhuys, Werner J.; Benkovic, Stanley A.; Lin, Li; Yonutas, Heather M.; Crish, Samuel D.; Sullivan, Patrick
G.; Darvesh, Altaf S.; Brown, Candice M.; and Richardson, Jason R., "MitoNEET (CISD1) Knockout Mice
Show Signs of Striatal Mitochondrial Dysfunction and a Parkinson's Disease Phenotype" (2017). Clinical
and Translational Science Institute. 862.
https://researchrepository.wvu.edu/ctsi/862

This Article is brought to you for free and open access by the Centers at The Research Repository @ WVU. It has
been accepted for inclusion in Clinical and Translational Science Institute by an authorized administrator of The
Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu.

Authors
Werner J. Geldenhuys, Stanley A. Benkovic, Li Lin, Heather M. Yonutas, Samuel D. Crish, Patrick G.
Sullivan, Altaf S. Darvesh, Candice M. Brown, and Jason R. Richardson

This article is available at The Research Repository @ WVU: https://researchrepository.wvu.edu/ctsi/862

HHS Public Access
Author manuscript
Author Manuscript

ACS Chem Neurosci. Author manuscript; available in PMC 2018 December 20.
Published in final edited form as:
ACS Chem Neurosci. 2017 December 20; 8(12): 2759–2765. doi:10.1021/acschemneuro.7b00287.

MitoNEET (CISD1) Knockout Mice Show Signs of Striatal
Mitochondrial Dysfunction and a Parkinson’s Disease Phenotype
Werner J. Geldenhuys*,†, Stanley A. Benkovic†, Li Lin‡, Heather M. Yonutas§, Samuel D.
Crish‡, Patrick G. Sullivan§, Altaf S. Darvesh‡, Candice M. Brown‖, and Jason R.
Richardson‡
†Department

Author Manuscript

of Pharmaceutical Sciences, School of Pharmacy, West Virginia University,
Morgantown, West Virginia 26506, United States

‡Department

of Pharmaceutical Sciences and Center for Neurodegenerative Disease and Aging,
Northeast Ohio Medical University, College of Pharmacy, Rootstown, Ohio 44272, United States
§Department

of Neuroscience; University of Kentucky Chandler College of Medicine, Lexington,
Kentucky 40536, United States

‖Department

of Microbiology, Immunology, and Cell Biology; School of Medicine, West Virginia
University, Morgantown, West Virginia 26506, United States

Abstract
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Mitochondrial dysfunction is thought to play a significant role in neurodegeneration observed in
Parkinson’s disease (PD), yet the mechanisms underlying this pathology remain unclear. Here, we
demonstrate that loss of mitoNEET (CISD1), an iron–sulfur containing protein that regulates
mitochondrial bioenergetics, results in mitochondrial dysfunction and loss of striatal dopamine and
tyrosine hydroxylase. Mitochondria isolated from mice lacking mitoNEET were dysfunctional as
revealed by elevated reactive oxygen species (ROS) and reduced capacity to produce ATP. Gait
analysis revealed a shortened stride length and decreased rotarod performance in knockout mice,
consistent with the loss of striatal dopamine. Together, these data suggest that mitoNEET KO mice
exhibit many of the characteristics of early neurodegeneration in PD and may provide a novel drug
discovery platform to evaluate compounds for enhancing mitochondrial function in
neurodegenerative disorders.
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INTRODUCTION
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder, which
affects more than a million people in the United States and approximately seven million
worldwide.1 PD is the second most prevalent neurodegenerative disease after Alzheimer’s
disease and is characterized by resting tremors, rigidity, and bradykinesia. These symptoms
greatly affect the quality of life of patients and place a heavy burden on the family and
health care systems. The clinical presentation is a result of the loss of dopaminergic neurons
in substantia nigra, pars compacta, and a concomitant loss of striatal dopamine levels.2 No
treatments are available to slow or stop the disease progression leading to a quest for
identifying new drug targets that may modify disease outcomes.3
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The etiology of PD remains to be fully elucidated, but current understanding points to both
genetic and environmental components.4 Irrespective of the origin, mitochondrial
dysfunction has been implicated to play a central role in the neurodegeneration of
dopaminergic cells.5–8 Mitochondria play a critical role in maintaining the energy balance of
neurons via oxidative phosphorylation. Elevated oxidative stress from reactive oxygen
species (ROS) generated by dysfunctional mitochondria has been linked to neuron loss and
abnormal mitophagy.8 Dysfunctional mitochondria that are not cleared may promote the
ROS environment and potentiate neuronal damage.4
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MitoNEET (CISD1) is an iron–sulfur (Fe–S) protein that was identified as an integral
component of the outer mitochondrial membrane.9 Studies suggest mitoNEET may act as a
redox-sensor for mitochondria.10 Additional functions proposed include maintenance of the
oxidative capacity of mitochondria isolated from cardiac cells and roles in obesity and type 2
diabetes.11–13 This study was initiated to evaluate the relationships between mitochondrial
dysfunction, dopaminergic markers, and PD as a result of loss of mitochondrial mitoNEET.

RESULTS AND DISCUSSION
Characterization of mitoNEET Knockout Mice
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Immunohistochemical evaluation of mitoNEET revealed decreased immunoreactivity in
mitoNEET KO mice (Figure 1B) as compared to wild-type (WT) mice (Figure 1A).
Densitometric analysis of immunoreactivity revealed a significant decrease in mitoNEET
staining as a result of gene deletion (Figure 1C, p < 0.05). Follow-up with Western blot
shows that the antibody has low cross-reactivity with CISD2 (Naf-1/miner1), which can be
seen in Figure 1D.14 This corroborates previously published data on these mice in a recent
study focused on the liver.15
Loss of mitoNEET Leads to Mitochondrial Dysfunction in Brain of KO Mice
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We evaluated the effects of loss of mitochondrial mitoNEET from striatal mitochondria
under normal conditions, where the respiration buffer was supplemented with pyruvate.
Mitochondria isolated from mitoNEET KO mice showed an increased production of reactive
oxygen species (Figure 2A), as well as superoxide (Figure 2B), compared to wild-type
animals. Elevated superoxide production in knockout mice was visualized by DHE staining
(Figure 2C). Deletion of mitoNEET decreased the ability of striatal mitochondria to produce
ATP by approximately 50% (Figure 2D). State III respiration was decreased in mitochondria
isolated from knockout mice by approximately 30% (Figure 2E) when compared to the
control mitochondria, and the respiratory control ratio (RCR) was decreased accordingly in
knockout mice (Figure 2F).
mitoNEET KO Mice Show a Decrease in Striatal Tyrosine Hydroxylase (TH) and Dopamine
Levels

Author Manuscript

We evaluated dopaminergic terminal integrity by analyzing the density of immunostaining
for tyrosine hydroxylase in the striatum of wild-type and knock out mice (Figure 3). At six
months, striatal TH levels were significantly decreased compared to control animals (p <
0.05). Deletion of mitoNEET resulted in an approximate 16% decrease in striatal TH
staining (Figure 3C). Decreased striatal TH immunostaining observed at six months was
accompanied by decreased tyrosine hydroxylase levels as evaluated by Western blotting
(Figure 3D). Levels of the housekeeping protein tubulin did not vary across animals.
Quantitation of blot data revealed an approximate 25% decrease in TH level following
mitoNEET knockout (Figure 3E).
Deletion of mitoNEET Causes Iron Accumulation in Striatum
Histological evaluation of iron staining revealed increased iron content in the striatum of
mitoNEET knockout mice at six months compared to wild-type animals (Figure 4). Levels
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of iron in knockout animals at one month did not differ from controls (data not shown). Most
of the iron was present in fibers of passage coursing through the striatum. Iron-containing
oligodendrocytes were observed among the fibers in both genotypes. These cells were round
or slightly oval and contained more iron at one end of the cell. Iron-containing processes
were observed throughout the neuropil and could be seen connecting to fiber bundles.
mitoNEET KO Mice Show Motor Deficits
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We evaluated gait and locomotor activity in mitoNEET KO and wild-type mice. Stride
length was significantly decreased by nearly two centimeters in the mitoNEET KO mice as
compared to wild-type controls (Figure 5A). mitoNEET KO mice fell from the rotarod in
approximately 20 s, as compared to wild-type control animals that remained on the rod for
nearly 95 s (Figure 5B). HPLC analysis of striatal homogenates revealed a significant
decrease in levels of dopamine (Figure 5C) at six months following deletion of mitoNEET
(p < 0.05).

CONCLUSION
We evaluated the effects of loss of the mitochondrial protein, mitoNEET, in mice and report
a progressive mitochondrial dysfunction and loss of immunoreactivity for TH in striatum at
six months of age. Deletion of mitoNEET caused an increase in ROS and superoxide levels
concomitant with decreased respiration and ATP production. Striatal dopamine levels were
decreased with an increase in age, and this was accompanied by behavioral deficits
associated with decreased dopamine levels. Thus, deletion of mitoNEET produces a
neurochemical and behavioral phenotype consistent with that observed with dopaminergic
neurodegeneration.
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MitoNEET was initially discovered as a ligand of the type-2 diabetes drug, pioglitazone. The
NEET family of proteins consists of three members, CISD1–3 (mitoNEET, Miner1, and
Miner2), which share the CDGSH domain that contains the Fe–S cluster characteristic of
this family. Recent characterization of NEET family function suggests these proteins are
involved in cluster transfer or electron transfer.16 Protonation of histidine residues can cause
release and transfer of an Fe–S cluster to an apo-acceptor protein; however, further research
is required to understand the physiological functions of these transfers.
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Mitochondrial dysfunction has been implicated in the loss of striatal dopamine and is
thought to contribute to the pathology associated with Parkinson’s disease.8 Previous studies
in cardiac myocytes and adipocytes revealed mitochondrial dysfunction following the loss of
mitoNEET.12 Conversely, overexpression of mitoNEET in adipocytes of ob/ob mice resulted
in increased uptake and storage of lipids and reduction of mitochondrial iron, ROS, and
inflammatory markers.13 These results suggest that mitoNEET plays an important role in
regulating the bioenergetics of mitochondria.
Deletion of mitoNEET was associated with a reduction in stride length and balance on the
rotarod suggesting that the loss of striatal dopamine is reflected in a dysfunction of motor
control in transgenic mice. The reduction in latency to fall was particularly striking,
approximately 10 s in knockout mice, suggesting balance is severely affected in these
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animals. Only one other study evaluated rotarod performance as a function of mitoNEET
deletion, and our data are consistent with latency times reported.17 Since PD is a movement
disorder, our results suggest that loss of mitoNEET interferes with the normal activity of
these neurons. Future studies will determine whether ligands of mitoNEET are able to
modulate behavioral parameters.

Author Manuscript

Mitochondrial dysfunction is implicated in the pathogenesis of PD.18 Our work supports the
hypothesis that mitoNEET is important to the proper function of mitochondria and that loss
of mitochondrial integrity is associated with increased ROS, decreased striatal TH
immunoreactivity and dopamine levels, and behavioral deficits. We observed that the
deletion of mitoNEET caused a temporal accumulation of iron in the striatum of knockout
mice compared to wild-type control animals. It seems likely that the increased iron is
responsible for the elevated ROS and superoxide production, which drives the pathology
associated with this manipulation. Iron is localized to the fibers of passage, which is the
same physical location as the nerve terminals that display immunoreactivity for tyrosine
hydroxylase. Perhaps the increased ROS and superoxide production produces a hostile
environment in the striatum that facilitates damage to the dopaminergic nerve terminals and
eventually causes their destruction and disappearance.
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Ligands of mitoNEET have shown promise in the modulation of mechanisms involved in
pathological processes.19 Known ligands belong to the thiazolidinedione (TZD) family;
however, this binding motif is not absolutely necessary for binding to mitoNEET.19 Our
laboratory has evaluated the ligand NL-1 and found it to be protective to cardiac stem cells
in an oxidative environment.20 Other studies investigating the ligand TT01001 have shown
protection from hyperglycemia, hyperlipidemia, and glucose intolerance in an animal model
of diabetes.21 Future studies aimed at discovering ligands of mitoNEET may result in
therapeutic interventions that are useful in the treatment of cancer, diabetes, Parkinson’s
disease, or other pathologies that feature ROS as a component of the mitochondrial
dysfunction.

METHODS
Animals

Author Manuscript

Mice were housed at Northeast Ohio Medical University (NEOMED). MitoNEET knockout
(KO) mice were obtained from Taconic Farms, were backcrossed to N9 on C57BL6/J mice
and bred as heterozygous mice. All animal experiments were done in accordance with the
NEOMED Institutional Animal Care and Use Committee (IACUC), protocol number
12-021. For each of the wild-type (WT) and mitoNEET KO (homozygous mice), the groups
consisted of five to seven mice to satisfy power analysis requirements and reflect an
acceptable standard error. Animals were sacrificed by decapitation for biochemical
experiments and overdose/perfusion for immunohistochemical experiments, at the age of six
months of age, and all the current mice were male.
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Mitochondrial respiration studies were performed as described previously.22 The brains were
removed, and the striata were dissected on a glass plate chilled by ice. Striata from two mice
were pooled and homogenized in isolation buffer (215 mM mannitol, 75 mM sucrose, 20
mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 1 mM ethylene glycolbis(β-amino-ethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) and 0.1% bovine serum
albumin (BSA), pH 7.2). Tissue homogenate was centrifuged for 3 min at 1300g, 4 °C, and
the supernatant was transferred to new centrifuge tube. The pellet was resuspended and
recentrifuged, and the supernatant was combined with the first collection. Pooled
supernatants were centrifuged for 10 min at 13000g, 4 °C. The pellet was resuspended in
isolation buffer without EGTA, layered onto a discontinuous Ficoll gradient (7.5%, 10%),
and centrifuged at 50000g for 30 min, 4 °C. The pellet was washed by resuspension in
isolation buffer without EGTA, and the solution was centrifuged for 10 min at 10000g to
obtain the final product. The pellet was resuspended in 50 μL of isolation buffer without
EGTA and was used in the respiration studies. Mitochondrial activity was measured in an
Oxytherm Clark-type electrode (Hansatech Instruments, UK). Respiration buffer consisted
of 125 mM KCl, 20 mM HEPES, 2 mM MgCl2 and 2.5 mM KH2PO4, pH 7.2. The rate of
oxygen consumption was measured by the addition of 2.5 μL of 2.5 mM pyruvate and 5 mM
malate and the addition of ADP, 1.25 μL of 150 μM (State III), followed by 1 μL of 1 μM
oligomycin (State IV). The respiratory control ratio (RCR) was determined by dividing State
III by State IV.
Mitochondrial Reactive Oxygen Species and Superoxide and ATP Detection
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Mitochondria were freshly isolated and purified for the ROS and superoxide experiments
from the striata of both WT and mitoNEET KO mice. The mitochondria were resuspended
in respiration buffer, and 50 μL samples were added to a 96-well black opaque bottom plate.
Baseline ROS activity was determined using an Amplex Red kit (A22188, Invitrogen,
Eugene, OR) and the protocol for H2O2 assay, including positive and negative controls.
Briefly, 50 μL of the working solution was added to each well, and the plate was incubated
for 30 min at room temperature in the dark. The fluorescence intensity was recorded in a
Cytation 3 plate reader (CYT3F, BioTek, Winooski, VT) with excitation at 550 nm and
emission detection at 590 nm. To detect baseline superoxide, 50 μL of 30 μM
dihydroethidium (DHE) (D1168, Molecular Probes, Thermo-Fisher, Waltham, MA) was
added to the wells, and the plate was incubated for 30 min at 37 °C. The fluorescence
intensity was measured in a Cytation 3 plate reader (CYT3F, BioTek, Winooski, VT) with
excitation at 400 nm and emission detection at 560 nm.23 For ATP, the same method was
used to isolate mitochondria, and the 50 mL samples were added to white opaque bottom
plates. To this was added ATP Glo (Promega, Madison WI), and the luminescence was read
in the Cytation 3 plate reader (CYT3F, BioTek, Winooski, VT).
Superoxide Detection in Vivo
To evaluate the presence of superoxide in the brain, mice received an intraperitoneal
injection of DHE (1.0 mg/kg in DMSO). Following a 4 h recovery, the brains were collected
and prepared for immunohistochemistry as described below.
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Brains from both WT and mitoNEET KO mice injected with DHE were cryoprotected
overnight in 20% sucrose in Dulbecco’s phosphate-buffered saline (DPBS), sectioned at 50
μm on a sliding microtome (AO860, American Optical), and mounted onto microscope
slides (ColorFrost+, Fisher Scientific, Pittsburgh, PA) unstained. The slides were covered
with a coverslip with VectaShield (Vector Laboratories, Burlingame, CA) and examined by
fluorescence microscopy.
Tissue Collection and Processing for Immunohistochemistry
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Mice were overdosed with sodium pentobarbital (ip injection) and perfused with 25 mL of
0.9% saline followed by 50 mL of 4% paraformaldehyde at 4 °C using a perfusion pump set
to 5.0 mL/min. The brains were removed from the skull from both the WT and mitoNEET
KO mice, postfixed in 4% paraformaldehyde for 24 h, and changed into DPBS. Brains
selected for paraffin processing were transferred into DPBS and prepared for shipping to
AML Laboratories (St. Augustine, FL). At AML, brains were processed, embedded in
paraffin, and sectioned at 15 μm using standard histological procedures.
Immunohistochemistry: Paraffin Sections
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Slides were processed through a standard deparaffination to water and incubated in an
antigen retrieval solution (10 mM citric acid, pH = 6.0) at 100 °C for 10 min. The solution
was allowed to cool, and the slides were rinsed in DPBS. The sections were outlined with a
hydrophobic pen (Fisher Scientific, Pittsburgh, PA) and processed for
immunohistochemistry using a modified ABC procedure (Vector Laboratories, Burlingame,
CA). Slides were transferred to a humidity chamber and treated with 10% methanol and
10% hydrogen peroxide in Dulbecco’s modified phosphate buffered saline (136 mM NaCl, 8
mM Na2HPO4, 2.6 mM KCl, 1.5 mM KH2PO4) for 15 min to quench endogenous
peroxidase. Following three rinses in DPBS for 5 min each, sections were incubated in a
permeabilizing solution (1.8% L-lysine, 4% normal horse serum, 0.2% Triton X-100 in
DPBS) for 30 min at room temperature. The solution was drained from the slide and
replaced with primary antibody solution in DPBS + 4% normal horse serum, and the slides
were incubated overnight in the humidity chamber at room temperature. The following day,
slides were rinsed three times in DPBS for 5 min each in a staining dish, then transferred
back to the chamber for incubation with secondary antibody solution in DPBS + 4% normal
horse serum for 2 h at room temperature. Following three rinses in DPBS, sections were
incubated in Avidin D-HRP (1:1000 in DPBS, Vector Laboratories, Burlingame, CA) in the
chamber for 1 h at room temperature, rinsed three times in DPBS, and incubated with
chromogen solution (3–3′ diaminobenzidine, 50 mg in 100 mL of DPBS + 50 μL of 30%
hydrogen peroxide (Electron Microscopy Sciences, Hatfield, PA) for 5 min. The slides were
rinsed in DPBS for 5 min, dehydrated through a standard histological series, and covered
with a coverslip with Permount (Fisher Scientific, Pittsburgh, PA). Antibodies investigated
are listed in Table 1.
Histochemical Detection of Iron
Iron levels were determined in brain sections of wild-type and knockout mice using a
modification of the Perl’s Prussian Blue stain with DAB enhancement.24 Briefly, slides were
deparaffinized to water, and were incubated in fresh Perl’s solution (1% potassium
ACS Chem Neurosci. Author manuscript; available in PMC 2018 December 20.
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ferrocyanide, pH = 1, 5% polyvinylpyrrolidone (PVP)) for 60 min with shaking. The slides
were rinsed in PBS three times for 5 min each and transferred to methanol containing 0.01
M sodium azide and 0.3% hydrogen peroxide for 60 min with shaking. Following three
rinses, slides were incubated in DAB solution (0.025% DAB, 0.12% hydrogen peroxide in
0.01 M Tris, pH = 7.4) for 30 min with shaking. The slides were rinsed three times as
described, dehydrated through a standard histological series, and covered with a coverslip
with Permount (Fisher Scientific, Pittsburgh, PA).
Microscopy
Slides were viewed on a Zeiss Axio Imager.Z2 microscope using AxioVision 4.8.2 software.
Images were captured with an AxioCam ICc1 at 20× and stored on a dedicated server.
Independent images were obtained for left and right striatum from approximately the same
location in the striatum.
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Image Analysis
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Images were viewed and analyzed in Photoshop CC2017.0.0 (Adobe Systems Inc., San Jose,
CA). To evaluate the density of immunostaining in striatum, images were converted to gray
scale and saved. A 0.5 × 0.5 cm2 square was drawn and dragged to ten random positions (in
the fibers of passage) in the striatum. The mean intensity of the immunostain was recorded
from the histogram at each of the ten positions. Intensity values were recorded in Excel
(Microsoft Corp., Redmond, WA) and subtracted from 276 (the maximum bright level) to
reconcile the inverse relationship between reduced staining and increased brightness. Left
and right striata were measured and recorded independently for each brain but were
combined at the analysis stage since the treatment (mitoNEET deletion) presumably affects
both hemispheres equally. The average staining density was calculated for each animal and
recorded in Excel.
Protein Determination and Western Blotting
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Striata were isolated from both the WT and mitoNEET KO mice and homogenized in cold
lysis buffer (10-fold wet weight) containing protease inhibitors and
phenylmethanesulfonylfluoride (PMSF). The homogenate was centrifuged for 15 min
(14000g, 4 °C), and the supernatant was removed to a new tube. Protein in the supernatant
was quantified using a BCA protein assay kit (23225, Pierce, ThermoFisher Scientific,
Waltham, MA). Ten micrograms of each sample was separated using a 4–12% miniPROTEAN precast gel running at 200 V for 35 min (Bio-Rad, Hercules, CA). The protein
was transferred to a poly(vinylidene fluoride) (PVDF) membrane at 100 V for 1 h. The
membrane was blocked for 1 h with reconstituted 5% nonfat dry milk in 0.2% TBST (Trisbuffered saline, 0.1% Tween 20). The membrane was incubated with a primary antibody
solution in TBST (rabbit anti-TH, 1:1000, Millipore, Billerica, MA) overnight at 4 °C,
washed for 5 min in PBS at room temperature, and incubated with a secondary antibody in
TBST (goat anti-rabbit IgG-HRP, 1:3000, Invitrogen, ThermoFisher Scientific, Waltham,
MA) for 1 h at room temperature. The blot was exposed to Pierce ECL Western blotting
substrate (32106, Pierce, ThermoFisher Scientific, Waltham, MA) and analyzed on a
FluorChem M chemiluminescent detector (92-15312-00, ProteinSimple, San Jose, CA).
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To determine levels of DA, striata were dissected out from both the WT and mitoNEET KO
mice and were weighed and placed in cold HClO4 (0.1 N, 500 μL, 4 °C). Tissue samples
were sonicated and centrifuged at 1200g for 5 min, and an aliquot was removed to measure
DA and 3,4-dihydroxyphenylacetic acid (DOPAC) by electrochemical detection. Biogenic
amines were separated on a Supelco column (Discovery C18, 10 cm × 3 mm × 5 μm) with a
20 μL injection loop. Samples were eluted with a degassed isogradient mobile phase (50
mM sodium acetate, 27.4 mM citric acid, 10 mM NaOH, 0.1 mM sodium octyl sulfate, 0.1
mM EDTA, and 5% MeOH in filtered deionized water, pH = 4.5, and filtered with a 0.45 μm
Millipore filter). Standards were diluted in 0.1 N perchloric acid in increments of 3.1, 6.2,
12.5, 25, 50, 100, 200, and 400 pg/20 μL. Chromatographs were analyzed using the ESA
501 program. The assay sensitivity (6.2–12.5 pg/20 μL) was determined by the presence of
detectable peaks above baseline noise.
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Stride Length Determination
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The consequences of mitoNEET deletion on motor function were evaluated by gait and
locomotor testing as performed previously.17,25 To analyze gait differences between the two
groups of mice, both the WT and mitoNEET KO mice were placed in a walkway that was
4.5 cm wide, 12 cm tall, and 40 cm long and allowed to walk toward a dark home box. The
front paws were dipped in orange ink and the back paws in black ink, and a white sheet of
paper was placed along the walkway. Each mouse was allowed to walk in the walkway
separately. The distances between steps were measured and recorded in Excel (Microsoft
Corporation, Redmond, WA). The ability of animals to maintain balance and motor
coordination was evaluated using the rotarod performance test.17 Time and speed parameters
were obtained from a dose–response of saline-injected wild-type mice and were at a point
prior to normal fatigue (150 s at 15 rpm). Mice were trained for 10 min at 5 rpm. The
latency to fall (number of seconds on the rod) was recorded in Excel, and average latencies
were calculated for each treatment group.
Statistical Analysis
Group means and standard errors were calculated with Prism 7.0c (GraphPad Software Inc.,
La Jolla, CA). Variance between means (WT and mitoNEET KO) was evaluated by Student t
test. Group means were considered different when p < 0.05.
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Figure 1.

Immunohistochemical evaluation of mitoNEET deletion. Immunolocalization of mitoNEET
revealed a near complete absence in knockout mice (B) compared to wild-type control
animals (A). Quantitative analysis of immunoreactivity revealed a significant decrease as a
result of mitoNEET deletion (C, p < 0.05). Scale bar = 50 μm. (D) Western Blot showing
depletion of mitoNEET in KO mice. Abbreviations are wild-type (WT); mitoNEET
knockout (KO).
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Figure 2.
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Loss of mitochondrial mitoNEET leads to mitochondrial dysfunction. Mitochondria from
mitoNEET KO mice showed increased production of ROS as measured by Amplex Red (A).
Superoxide levels measured by DHE were higher in mitochondria isolated from mitoNEET
KO mice (B). In vivo staining of the striatum with DHE showed increased superoxide levels
(C). Mitochondria isolated from knockout mice showed decreased ATP production
compared to wild-type control animals (D). State III respiration was decreased in
mitochondria isolated from mitoNEET KO mice (E) and RCR was reduced (F). Data are
mean ± SEM where N = 5–7 mice. *Statistical significance P < 0.05.
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Figure 3.
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Tyrosine hydroxylase is reduced in mitoNEET KO striatum. mitoNEET deletion caused a
temporal reduction in immunostaining for tyrosine hydroxylase in the striata of mice. At six
months of age, knockout mice showed reduced TH immunostaining in the striatum (WT
mice (A) and mitoNEET KO mice (B)). TH densitometric analysis of immunostaining
revealed a significant reduction (p < 0.05) in levels of TH immunoreactivity (C). Scale bar =
60 μm. Striatal tyrosine hydroxylase levels were reduced in mitoNEET KO mice (D)
compared to WT mice when TH was normalized to the housekeeping gene tubulin.
Quantitative analysis of Western blot data revealed an approximate 25% decrease in TH of
knockout mice (E). Data are mean ± SEM where n = 5–7 mice. *Statistical significance P <
0.05. Abbreviations are wild-type (WT); mitoNEET knockout (KO).

Author Manuscript
ACS Chem Neurosci. Author manuscript; available in PMC 2018 December 20.

Geldenhuys et al.

Page 15

Author Manuscript

Figure 4.

Author Manuscript

Iron accumulates following deletion of mitoNEET. Evaluation of iron staining in striatum
revealed an accumulation of iron in mitoNEET knockout mice at six months of age (B)
compared to control animals (A). Iron staining was observed in the fibers of passage and
oligodendrocytes that are located at the borders of the fascicles. Iron-containing cells
accumulate the metal at one pole of the cell. Little to no staining was observed in the matrix
of either genotype but processes can be observed coursing from iron-positive cells to the
fiber bundles. Scale bar = 50 μm.
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Figure 5.
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Behavior and neurochemical analysis of mitoNEET knockout mice. (A) The stride length of
mice was decreased significantly following the deletion of mitoNEET. (B) Transgenic mice
were less able to maintain balance on the rotarod and fell from the rod quicker than wildtype control animals. (C) HPLC analysis of striatal homogenates revealed a significant
decrease in levels of dopamine at six months following deletion of mitoNEET. Data are
mean ± SEM where N = 5–7 mice. *Statistical significance P < 0.05. Abbreviations are
wild-type (WT); mitoNEET knockout (KO).
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